D-index as a Predictor of Complication of Treatment of Patients With Acute Myeloid Leukemia
NCT06188182 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 60
Last updated 2024-01-03
Summary
1. The effect of D-index on the onset and severity of FN in AML patients.
2. Relationship between the c-D-index and duration of FN in AML patients.
3. Correlation between D-index and MDR.
4. Correlation between D-index and invasive fungal infection.
5. Comparison of FN in different treatment protocols for AML using D-index.
6. Prediction of pulmonary, fungal or blood stream infection.
Conditions
- AML, Adult
Sponsors & Collaborators
-
Assiut University
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-06-01
- Primary Completion
- 2025-06-01
- Completion
- 2026-06-30
More Related Trials
-
Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome
NCT01311258 ·Status: RECRUITING
-
Maintenance Azacitidine in Elderly Patients With Acute Myeloid Leukemia (AML) in CR After Induction Chemotherapy
NCT00387647 ·Status: COMPLETED ·Phase: PHASE2
-
What is the Prognostic Value of HALP Score, Monocytopenia, Hypofibrinogenemia, and AST/ALT Ratio in Patients With Myelodysplastic Syndromes
NCT07210034 ·Status: NOT_YET_RECRUITING
-
Outcomes of Acute Myeloid Leukemia Patients
NCT04392310 ·Status: UNKNOWN
-
IDH1/IDH2 Mutation Frequency in Acute Myeloblastic Patients
NCT03204838 ·Status: UNKNOWN
-
Observational Study for the Evaluation of Incidence of Familial AML/MDSs in Patients With Myeloid Neoplasms
NCT04460950 ·Status: RECRUITING
-
Validation Study of a New Cytokine-based Dynamic Stratification Based on FLt3 Ligand Plasma Concentration Kinetic Profile and IL-6 Concentration During Induction of Acute Myeloid Leukemia
NCT04641910 ·Status: COMPLETED
-
A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy
NCT02677922 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Prospective Study on Severe Infections on Acute Myeloid Leukemia (AML) Patients
NCT01570465 ·Status: TERMINATED
-
Prognostic Factors and the Impact of Various Management of Acute Myeloid Leukemia in Real Life Condition
NCT03284593 ·Status: ACTIVE_NOT_RECRUITING
-
CD155 Expression in Acute Myeloid Leukemia
NCT06369662 ·Status: COMPLETED
-
Comparison Between Two Dose Levels of Daunorubicin and Between One vs. Two Induction Cycles for Adult Patients With AML
NCT02140242 ·Status: COMPLETED ·Phase: PHASE3
-
Italian Registry on the Prevalence of IDH1/IDH2 Mutations in Patients With Acute Myeloid Leukemia
NCT02986620 ·Status: COMPLETED
-
High Dose Daunorubicin Vs. Standard Dose Daunorubicin in Induction Treatment of AML
NCT00474006 ·Status: COMPLETED ·Phase: PHASE3
-
Invasives Aspergillosis in Acute Myeloid Leukemia
NCT02900430 ·Status: COMPLETED
-
Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients
NCT01929408 ·Status: COMPLETED
-
Optimizing Induction Chemotherapy Regimens for ND Elderly AML Patients Who Are Eligible for Intense Chemotherapy
NCT06066242 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Clinical Characters and Outcome of Acute Myeloid Leukemia Patients on Correlation to CD200 and CD56 Expression
NCT05512104 ·Status: UNKNOWN
-
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
NCT00424983 ·Status: COMPLETED ·Phase: PHASE1
-
Exploring Disease Immunogenicity and the Immunological Effects of Hypomethylating Agents in Acute Myeloid Leukemia
NCT03789981 ·Status: ACTIVE_NOT_RECRUITING
-
Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events
NCT05224661 ·Status: ACTIVE_NOT_RECRUITING
-
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
NCT02074839 ·Status: RECRUITING ·Phase: PHASE1
-
Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT02316964 ·Status: COMPLETED ·Phase: PHASE1
-
Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML
NCT02560025 ·Status: COMPLETED ·Phase: PHASE2
-
Biomarkers in Blood Samples From Patients With Acute Myeloid Leukemia
NCT01385150 ·Status: COMPLETED